Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924664 · ClinicalTrials.gov registry record · Phase 2
Long Term Safety Study of Tanezumab in Chronic Low Back Pain
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 849
- Enrollment target
NCT00924664: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT00924664 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 849 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (538% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00924664, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 849 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of tanezumab for chronic low back pain. Patients who were randomized and treated with study medication in a previous chronic low back pain "parent" study will be eligible to enroll in this safety extension study at the Preferred Rollover Time Point visit or at the Early Termination visit of the parent study upon discontinuation due to lack of efficacy.
Primary Outcome
AE: any untoward medical occurrence in participant who received study medication without regard to possibility of causal relationship. SAE: AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study medication and up to 112 days after l
Interventions
- BIOLOGICAL Tanezumab 20 mg
- BIOLOGICAL Tanezumab 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 849 participants |
| Start Date | 2009-08-20 |
| Est. Completion | 2011-06-22 |
| Phase | Phase 2 |
Why NCT00924664 stopped before completion
NCT00924664 is an interventional study that assigns participants to a tested intervention. The registered 849 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (538% higher).
The record links to 0 conditions, and to 2 interventions - of which Tanezumab 20 mg is the first listed.
NCT00924664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00924664 about?
NCT00924664 is a clinical study titled "Long Term Safety Study of Tanezumab in Chronic Low Back Pain". The purpose of this study is to investigate the safety and efficacy of tanezumab for chronic low back pain. Patients who were randomized and treated with study medication in a previous chronic low back pain "parent" study will be eligible to enroll in this safety extension study at the Preferred Rol...
What is the current status of trial NCT00924664?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 849 participants. The study started on 2009-08-20. Estimated completion is 2011-06-22.
What interventions are being tested in trial NCT00924664?
The interventions under investigation include: Tanezumab 20 mg (BIOLOGICAL), Tanezumab 10 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00924664?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00924664's enrollment target sits among peer trials
849 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI